Paragon launches biopharmaceutical companies that embody our core value of patient-centric, biomedical innovation.
LAUNCHED BY PARAGON
Castle Creek Biosciences
Castle Creek Biosciences employs a unique strategy in selective asset identification and capital efficient development that is driving the company to become one of the industry’s most prolific developers of innovative and high potential late stage therapies for rare genetic dermatology conditions. For more information, please visit https://castlecreekbio.com/
Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.
Emalex is committed to developing effective treatments for the Central Nervous System (CNS). Emalex’s focus is on making lives easier for the courageous people living with CNS disorders. For more information, please visit www.emalexbiosciences.com.
Evozyne is a world-leading company that creates novel proteins with exceptionally advanced functionality based on data-driven molecular engineering. Evozyne is working with some of the largest and most innovative companies to solve their pressing challenges. For more information, please visit www.evozyne.com.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on therapies for sleep and cognitive disorders, Harmony’s goal is to push the boundaries of what science can do to improve the lives of patients. For more information, please visit www.harmonybiosciences.com.
Developing the latest therapies for those living with serious immunology conditions.
Qlarity Imaging improves patient care by building AI-driven products that provide clinical insights which radiologists do not have access to today. One of Qlarity’s initial products, QuantX Advanced, is the first FDA-cleared, computer-aided breast cancer diagnosis software for radiology. For more information, please visit www.qlarityimaging.com.
Skyline Biosciences is developing first in-kind oncology therapies to treat premalignant and malignant conditions with unmet medical need. Skyline’s mission is to alleviate potentially life-threatening conditions and to improve the quality of life for the patients it serves. For more information, please visit www.skylinebiosciences.com.